HK1246786A1 - 吡咯并吡啶化合物的结晶形式 - Google Patents

吡咯并吡啶化合物的结晶形式 Download PDF

Info

Publication number
HK1246786A1
HK1246786A1 HK18106266.4A HK18106266A HK1246786A1 HK 1246786 A1 HK1246786 A1 HK 1246786A1 HK 18106266 A HK18106266 A HK 18106266A HK 1246786 A1 HK1246786 A1 HK 1246786A1
Authority
HK
Hong Kong
Prior art keywords
crystalline forms
pyrrolopyridine compound
pyrrolopyridine
compound
aminopiperidin
Prior art date
Application number
HK18106266.4A
Other languages
English (en)
Chinese (zh)
Inventor
Stults Jeffrey
M. Lindemann Christopher
L. Spencer Keith
Liu Weidong
LUBACH Joseph
Original Assignee
Genentech, Inc.
Array Biopharma Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55521844&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1246786(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech, Inc., Array Biopharma Inc. filed Critical Genentech, Inc.
Publication of HK1246786A1 publication Critical patent/HK1246786A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
HK18106266.4A 2015-02-26 2016-02-26 吡咯并吡啶化合物的结晶形式 HK1246786A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562121396P 2015-02-26 2015-02-26
US62/121,396 2015-02-26
PCT/US2016/019904 WO2016138458A1 (en) 2015-02-26 2016-02-26 Crystalline forms of a pyrrolopyridine compound

Publications (1)

Publication Number Publication Date
HK1246786A1 true HK1246786A1 (zh) 2018-09-14

Family

ID=55521844

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18106266.4A HK1246786A1 (zh) 2015-02-26 2016-02-26 吡咯并吡啶化合物的结晶形式

Country Status (21)

Country Link
US (2) US20160251350A1 (https=)
EP (1) EP3262042A1 (https=)
JP (1) JP2018506562A (https=)
KR (1) KR20170118762A (https=)
CN (1) CN107406447A (https=)
AR (1) AR103801A1 (https=)
AU (1) AU2016225070A1 (https=)
BR (1) BR112017018230A2 (https=)
CA (1) CA2976665A1 (https=)
CL (1) CL2017002180A1 (https=)
CO (1) CO2017009662A2 (https=)
CR (1) CR20170439A (https=)
HK (1) HK1246786A1 (https=)
IL (1) IL254115A0 (https=)
MA (1) MA41599A (https=)
MX (1) MX2017010888A (https=)
PE (1) PE20171327A1 (https=)
PH (1) PH12017501532A1 (https=)
RU (1) RU2017133093A (https=)
SG (1) SG11201706824TA (https=)
WO (1) WO2016138458A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115385871A (zh) * 2019-01-29 2022-11-25 沪亚生物国际有限公司 舒欣啶盐
EP3923948A4 (en) * 2019-02-12 2022-11-16 Impact Biomedicines, Inc. CRYSTALLINE SHAPES OF A JAK2 INHIBITOR

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
AR071717A1 (es) 2008-05-13 2010-07-07 Array Biopharma Inc Pirrolo[2,3-b]piridinas inhibidoras de quinasas chk1 y chk2,composiciones farmaceuticas que las contienen,proceso para prepararlas y uso de las mismas en el tratamiento y prevencion del cancer.
US8481557B2 (en) * 2009-04-11 2013-07-09 Array Biopharma Inc. Method of treatment using checkpoint kinase 1 inhibitors
ES2621857T3 (es) * 2010-11-16 2017-07-05 Array Biopharma, Inc. Combinación de inhibidores de la cinasa 1 de punto de control e inhibidores de la cinasa WEE1
KR102325163B1 (ko) * 2013-08-22 2021-11-11 제넨테크, 인크. 화합물의 제조 방법
WO2015027090A1 (en) * 2013-08-22 2015-02-26 Genentech, Inc. Intermediates and processes for preparing compounds

Also Published As

Publication number Publication date
CL2017002180A1 (es) 2018-03-16
KR20170118762A (ko) 2017-10-25
PE20171327A1 (es) 2017-09-12
WO2016138458A1 (en) 2016-09-01
IL254115A0 (en) 2017-10-31
AR103801A1 (es) 2017-06-07
SG11201706824TA (en) 2017-09-28
PH12017501532A1 (en) 2018-02-05
MA41599A (fr) 2018-01-02
AU2016225070A1 (en) 2017-09-07
US20160251350A1 (en) 2016-09-01
US20180282324A1 (en) 2018-10-04
BR112017018230A2 (pt) 2018-04-17
JP2018506562A (ja) 2018-03-08
EP3262042A1 (en) 2018-01-03
CR20170439A (es) 2018-01-08
MX2017010888A (es) 2017-12-15
RU2017133093A (ru) 2019-03-26
CN107406447A (zh) 2017-11-28
CO2017009662A2 (es) 2018-02-28
RU2017133093A3 (https=) 2019-08-23
CA2976665A1 (en) 2016-09-01

Similar Documents

Publication Publication Date Title
SA520411524B1 (ar) مركبات تنشيط القسيم العضلي ثنائي الأميد واستخداماتها
WO2015200677A8 (en) Prmt5 inhibitors and uses thereof
WO2016011390A8 (en) Irak4 inhibiting agents
ZA201907687B (en) Salt of an aminopyridine derivative compound, a crystalline form thereof, and a process for preparing the same
PH12017502376A1 (en) Oral solid formulation containing irinotecan and method of preparing the same
PH12017501699A1 (en) Fused bicyclic heteroaryl derivatives having activity as phd inhibitors
WO2015142903A3 (en) Method of controlling lactate production with piperdine-dione derivatives
MX2019012454A (es) Compuesto solido cristalino novedoso de clorhidrato de 3-fenil-4-propil-1-(piridin-2-il)-1h-pirazol-5-ol.
IL285277A (en) History of imidazoquinolines and their use
IL276430A (en) A pharmaceutical compound, its cures, its formulations, and methods for its preparation and use
WO2015121877A3 (en) Polymorphs of lomitapide and its salts
WO2013169746A3 (en) N-ethyl-4-hydroxyl-1-methyl-5- (methyl(2,3,4,5,6-pentahydroxyhexyl) amino) -2-oxo-n-phenyl-1,2-dihydroquinoline-3-carboxamide
WO2015191681A3 (en) Substituted pyridinones as mgat2 inhibitors
PH12019500567B1 (en) Crystalline forms
HK1246786A1 (zh) 吡咯并吡啶化合物的结晶形式
MX2018015990A (es) Compuestos terapeuticos.
WO2014195977A3 (en) Novel polymorphs of vismodegib
WO2013182946A3 (en) Vilazodone hydrobromide, process for its preparation and vilazodone polymorphs
WO2012038971A3 (en) Novel polymorphs of febuxostat
MX375758B (es) Sales y polimorfos de un compuesto imidazopiridinil-aminopiridina sustituido.
WO2017029642A3 (en) Novel polymorphs of dolutegravir and salts thereof
SG11202111558VA (en) Crystalline form of compound, method for preparing the same, pharmaceutical composition and use
WO2016004911A8 (en) A cocrystal of ivabradine hydrochloride and (r)-mandelic acid and its pharmaceutical composition
HK40075950A (en) Crystalline forms of quinoline analogs and salts thereof, compositions, and their methods for use
WO2019004979A3 (en) SOLID ORAL PHARMACEUTICAL COMPOSITIONS OF DABIGATRAN DEXILATE